191 related articles for article (PubMed ID: 29525381)
1. Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis.
Dabestani S; Beisland C; Stewart GD; Bensalah K; Gudmundsson E; Lam TB; Gietzmann W; Zakikhani P; Marconi L; Fernandéz-Pello S; Monagas S; Williams SP; Torbrand C; Powles T; Van Werkhoven E; Meijer R; Volpe A; Staehler M; Ljungberg B; Bex A
Eur Urol Focus; 2019 Sep; 5(5):857-866. PubMed ID: 29525381
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
[TBL] [Abstract][Full Text] [Related]
3. Potentially curable recurrent disease after surgically managed non-metastatic renal cell carcinoma in low-, intermediate- and high-risk patients.
Kuijpers YA; Meijer RP; Jonges GN; de Jong J; Bosch JL; Horenblas S; Bex A
World J Urol; 2016 Aug; 34(8):1073-9. PubMed ID: 27055532
[TBL] [Abstract][Full Text] [Related]
4. Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR).
Dabestani S; Beisland C; Stewart GD; Bensalah K; Gudmundsson E; Lam TB; Gietzmann W; Zakikhani P; Marconi L; Fernandéz-Pello S; Monagas S; Williams SP; Torbrand C; Powles T; Van Werkhoven E; Meijer R; Volpe A; Staehler M; Ljungberg B; Bex A
Eur Urol; 2019 Feb; 75(2):261-264. PubMed ID: 30318330
[TBL] [Abstract][Full Text] [Related]
5. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial.
Narayan V; Puligandla M; Haas NB; Subramanian P; DiPaola RS; Uzzo R
J Urol; 2019 Jan; 201(1):62-68. PubMed ID: 30130544
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.
Siva S; Bressel M; Wood ST; Shaw MG; Loi S; Sandhu SK; Tran B; A Azad A; Lewin JH; Cuff KE; Liu HY; Moon D; Goad J; Wong LM; LimJoon M; Mooi J; Chander S; Murphy DG; Lawrentschuk N; Pryor D
Eur Urol; 2022 Apr; 81(4):364-372. PubMed ID: 34953600
[TBL] [Abstract][Full Text] [Related]
8. Patterns of Presentation and Treatment Outcomes of Non-clear-cell Renal Cell Carcinoma and Sarcomatoid Renal Cell Carcinoma Patients in 2 Tertiary Referral Centers in Sydney, Australia.
Naher S; Padinharakam S; Balakrishnar B; Chua W; Descallar J; Adams D; de Souza P; Harrison M; Lim S
Clin Genitourin Cancer; 2019 Jun; 17(3):e565-e569. PubMed ID: 30935815
[TBL] [Abstract][Full Text] [Related]
9. Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence.
Grüllich C; Vallet S; Hecht C; Duensing S; Hadaschik B; Jäger D; Hohenfellner M; Pahernik S
Urol Oncol; 2016 May; 34(5):238.e9-17. PubMed ID: 26739671
[TBL] [Abstract][Full Text] [Related]
10. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.
Klatte T; Gallagher KM; Afferi L; Volpe A; Kroeger N; Ribback S; McNeill A; Riddick ACP; Armitage JN; 'Aho TF; Eisen T; Fife K; Bex A; Pantuck AJ; Stewart GD
BMC Med; 2019 Oct; 17(1):182. PubMed ID: 31578141
[TBL] [Abstract][Full Text] [Related]
11. Low Rate of Cancer Events After Partial Nephrectomy for Renal Cell Carcinoma: Clinicopathologic Analysis of 1994 Cases with Emphasis on Definition of "Recurrence".
Bertolo R; Nicolas M; Garisto J; Magi-Galluzzi C; McKenney JK; Kaouk J
Clin Genitourin Cancer; 2019 Jun; 17(3):209-215.e1. PubMed ID: 31000486
[TBL] [Abstract][Full Text] [Related]
12. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
Psutka SP; Feldman AS; McDougal WS; McGovern FJ; Mueller P; Gervais DA
Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
[TBL] [Abstract][Full Text] [Related]
13. Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups.
Marconi L; Kuusk T; Capitanio U; Beisland C; Lam T; Pello SF; Stewart GD; Klatte T; Volpe A; Ljungberg B; Dabestani S; Bex A
Eur Urol Open Sci; 2023 Jan; 47():65-72. PubMed ID: 36601038
[TBL] [Abstract][Full Text] [Related]
14. Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy.
Verbiest A; Couchy G; Job S; Caruana L; Lerut E; Oyen R; de Reyniès A; Tosco L; Joniau S; Van Poppel H; Van Raemdonck D; Van Den Eynde K; Wozniak A; Zucman-Rossi J; Beuselinck B
Eur Urol; 2018 Oct; 74(4):474-480. PubMed ID: 29463434
[TBL] [Abstract][Full Text] [Related]
15. Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes.
Psutka SP; Heidenreich M; Boorjian SA; Bailey GC; Cheville JC; Stewart-Merrill SB; Lohse CM; Atwell TD; Costello BA; Leibovich BC; Thompson RH
BJU Int; 2017 Jan; 119(1):116-127. PubMed ID: 27489013
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
17. Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinoma.
Blackmur JP; Gaba F; Fernando D; Williams S; O'Donnell M; McNeill A; Stewart GD; Leung S; Laird A
Urol Oncol; 2021 Jul; 39(7):438.e11-438.e21. PubMed ID: 34023196
[TBL] [Abstract][Full Text] [Related]
18. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
Lee Z; Jegede OA; Haas NB; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Flaherty KT; Dutcher JP; DiPaola RS; Uzzo RG
J Urol; 2020 Apr; 203(4):684-689. PubMed ID: 31596672
[TBL] [Abstract][Full Text] [Related]
19. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
[TBL] [Abstract][Full Text] [Related]
20. Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.).
Dabestani S; Beisland C; Stewart GD; Bensalah K; Gudmundsson E; Lam TB; Gietzmann W; Zakikhani P; Marconi L; Fernandéz-Pello S; Monagas S; Williams SP; Powles T; Van Werkhoven E; Meijer R; Volpe A; Staehler M; Ljungberg B; Bex A
Scand J Urol; 2019 Feb; 53(1):14-20. PubMed ID: 30907214
[No Abstract] [Full Text] [Related]
[Next] [New Search]
